Scientech Research LLC Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Scientech Research LLC acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,592 shares of the biopharmaceutical company’s stock, valued at approximately $759,000.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $40,000. NEOS Investment Management LLC purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth $210,000. North Star Asset Management Inc. bought a new stake in Agios Pharmaceuticals in the second quarter valued at $216,000. Finally, XTX Topco Ltd purchased a new position in Agios Pharmaceuticals during the 2nd quarter valued at $230,000.

Agios Pharmaceuticals Stock Down 5.1 %

AGIO stock opened at $45.61 on Friday. The business has a 50 day moving average of $45.68 and a 200 day moving average of $39.74. The firm has a market cap of $2.59 billion, a PE ratio of -7.22 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a twelve month low of $19.80 and a twelve month high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. Agios Pharmaceuticals’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.51) EPS. On average, research analysts expect that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 11,091 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AGIO shares. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. The Goldman Sachs Group increased their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 4th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday. Finally, Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $60.00 to $56.00 in a report on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $52.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.